Nmv Desen Biotech

NMV Biotech (also known as NMV-Desen Biotech) is a clinical-stage biotechnology company based in Guangzhou, China, focused on the development of mRNA-based vaccines and therapeutics. The company leverages a proprietary lipid nanoparticle (LNP) delivery platform and advanced mRNA synthesis technologies to address infectious diseases and oncology. Its lead candidate, NMV-101, is an mRNA vaccine for COVID-19 that has entered clinical evaluation. Beyond infectious diseases, NMV Biotech is advancing a pipeline of personalized cancer vaccines and other prophylactic vaccines for conditions such as shingles and rabies. The company represents a significant player in the emerging Chinese mRNA ecosystem, aiming to provide domestically developed alternatives to global mRNA platforms.